Fox Run Management L.L.C. Makes New $863,000 Investment in Illumina, Inc. $ILMN

Fox Run Management L.L.C. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 6,580 shares of the life sciences company’s stock, valued at approximately $863,000.

Other hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC purchased a new position in shares of Illumina during the fourth quarter worth about $25,000. Creative Capital Management Investments LLC grew its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Illumina during the fourth quarter worth about $26,000. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina during the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in shares of Illumina during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other news, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares in the company, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock opened at $162.47 on Thursday. The firm has a 50 day moving average of $140.11 and a 200-day moving average of $134.50. Illumina, Inc. has a 12-month low of $85.77 and a 12-month high of $177.22. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a market cap of $24.58 billion, a price-to-earnings ratio of 29.54, a PEG ratio of 3.00 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm earned $0.97 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of several research reports. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $185.00 in a report on Wednesday. Barclays increased their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Citigroup increased their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Finally, Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $142.13.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.